CGP4540(Amoscanate)

Amoscanate (cgp4540) is phenyl isothiocyanate in which the hydrogen at the para-position has been replaced by a 4-nitroanilinyl group. Amoscanate is an anti-schistosomal agent. Amoscanate, as an isothiocyanate compound and uncoupler of oxidative phosphorylation, potently injures rodent ependyma[1].

Research Areas >> Others

Signaling Pathways >> Others >> Others

Amoscanate (500 mg/kg; p.o.; 10 days) destructs ependyma and periventricular brain[1]. Amoscanate (250 and 500 mg/kg; p.o.; 28 days) elicits necrosis, Ca++-positive microgranules, pyknosis and edema localized in ependyma/subependyma in the medial striatum[1]. Amoscanate (25~500 mg/kg; p.o.; 20 days) elicits progressive necrosis of ependyma[1]. Amoscanate elicits massive ultrastructural damage in ependymal cells[1]. Animal Model: Sprague-Dawley rats[1] Dosage: 500 mg/kg Administration: P.o.; 10 days Result: Destructed ependyma and periventricular brain. Animal Model: Sprague-Dawley rats[1] Dosage: 250 and 500 mg/kg Administration: P.o.; 28 days Result: Elicited necrosis, Ca++-positive microgranules, pyknosis and edema localized in ependyma/subependyma in the medial striatum. Animal Model: Sprague-Dawley rats[1] Dosage: 25~500 mg/kg Administration: P.o.; 20 days Result: Elicited progressive necrosis of ependymal.

[1]. Johanson C, et al. The distributional nexus of choroid plexus to cerebrospinal fluid, ependyma and brain: toxicologic/pathologic phenomena, periventricular destabilization, and lesion spread. Toxicol Pathol. 2011;39(1):186-212.